Displaying 158 (all) recruiting clinical trials.
-
A Phase 1/2 First-in-Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
This study is designed for patients who have Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway MutationsThe objective of the study is to ...
-
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
This study is designed for patients diagnosed with advanced solid tumors and is testing a novel epigenetic modifying strategy to restore tumor cell differentiation.
The ...
-
PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER AT LEAST ONE LINE OF SYSTEMIC THERAPY
The purpose of the study is to evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M +Len) compared with rituximab in combination ... -
A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients with Advanced Malignancies
This is a study to test a new medicine called CDX-585 on patients with advanced or spreading solid tumors that have not improved with current ...
-
EVEREST-1: A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530 an Autologous Logic-gated Tmod Chimeric Antigen Receptor T Cell (CAR T) in Heterozygous HLA-A*02 Adult Subjects with Recurrent Unresectable Locally Advanced or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
This is a study to see if a new treatment called A2B530 is safe and effective for people with certain types of cancer that have ...
-
A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA
This is a study to test a drug called selinexor for patients with EC (endometrial carcinoma). The drug will be given to patients who have ...
-
A Phase 1/2 Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination with an anti-PD-1 Antibody in Patients with STK11-Mutated Advanced Solid Tumors
This study is testing a new drug called TNG260 (a specific medicine referred to as a CoreDAC inhibitor that can undo the way the immune ...
-
A Phase 1 Open-Label Multi-Center Safety and Efficacy Study of PRT3789 in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
This is a study to test a new drug called PRT3789 for safety and effectiveness in treating certain types of advanced or metastatic solid tumors ...
-
Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
This study is about testing a combination of drugs (gemcitabine, nab-paclitaxel, VS-6766, and defactinib) to treat a type of cancer called pancreatic ductal adenocarcinoma (PDAC ...
-
A SINGLE-ARM PHASE 2 STUDY OF DARATUMUMAB IN PREVIOUSLY TREATED STK11/LKB1 MUTATED NON-SMALL CELL LUNG CANCER
This is a study of a drug combination called daratumumab for patients with advanced lung cancer that has spread to other parts of the body ...